DNA Extraction And Library Preparation: Genomic DNA undergoes fragmentation followed by targeted capture of sequences corresponding to exonic regions via hybridization-based probes.
Sequencing: Captured DNA processes through massively parallel short-read sequencing simultaneously, generating millions of reads.
Bioinformatic Pipeline: Raw data (FASTQ) undergoes alignment to a reference human genome (hg38/GRCh38), variant calling, and annotation using specialized software.
Variant Prioritization: Analysts filter thousands of variants utilizing population databases, disease-causing databases, and phenotype matching via Human Phenotype Ontology (HPO) terms.
Trio Sequencing: Simultaneous testing of the proband and both biological parents (Trio-WES) constitutes the gold standard, effectively determining segregation patterns and readily identifying de novo or compound heterozygous mutations.
Turnaround Time: Standard reporting requires 2-8 weeks, whereas rapid WES for critically ill neonates yields results within 48-72 hours.
Clinical Indications
Category
Specific Clinical Scenarios
Neurodevelopmental Disorders
Unexplained global developmental delay, intellectual disability, and autism spectrum disorder after negative chromosomal microarray.
Complex Phenotypes
Multiple congenital anomalies or dysmorphic features lacking a clearly recognizable syndromic pattern.
Inborn errors of metabolism with negative biochemical screening or atypical features of known conditions.
Dual Diagnoses
Patients exhibiting two or more unrelated phenotypes suggesting oligogenic conditions.
Neonatal Intensive Care
Critically ill infants requiring rapid diagnosis for time-sensitive, life-altering medical management decisions.
Diagnostic Yield And Advantages
Provides a robust diagnostic yield ranging from 25% to 40% in previously undiagnosed dysmorphic, intellectual disability, and multiple congenital anomaly cases.
Proves highly cost-effective, effectively ending the prolonged diagnostic odyssey associated with sequential single-gene testing.
Facilitates the discovery of novel disease-gene associations.
Enables targeted precision therapy initiation, guides medical surveillance protocols, and provides precise recurrence risk counseling.
Periodic reanalysis of existing exome data every 6-12 months yields an additional 10-15% diagnostic success due to continuously updated gene-disease associations.
Variant Interpretation
Classification follows American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines.
Assigns variants into five tiers: Pathogenic, Likely pathogenic, Variant of Uncertain Significance (VUS), Likely benign, and Benign.
Utilizes evidence tiers comprising very strong (null variant), strong (de novo), moderate (population frequency), and supporting (computational predictions) criteria.
Limitations And Ethical Considerations
Limitation Category
Clinical Impact
Coverage Gaps
Strictly evaluates targeted coding regions, missing pathogenic variants in deep intronic, regulatory, promoter regions, and epigenetic/imprinting disorders.
Structural Variants
Possesses limited sensitivity for detecting large structural variations, translocations, inversions, and triplet repeat expansions compared to whole genome sequencing or chromosomal microarray.
Variant Of Uncertain Significance
Identifies massive amounts of genetic variation (frequently >30,000 VUS per individual), requiring extensive functional evidence and expert bioinformatic correlation to determine true pathogenicity.
Incidental Findings
May uncover pathogenic variants completely unrelated to the primary clinical indication, such as actionable adult-onset cancer predisposition genes.
Mandatory pre-test genetic counseling must address expectations regarding diagnostic yield, limitations, and specific family preferences regarding the disclosure of medically actionable incidental findings.
